Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Praxis Precision Medicines's Ulixacaltamide?
Ulixacaltamide is a small molecule commercialized by Praxis Precision Medicines, with a leading Phase III program in Essential Tremor. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Praxis Precision Medicines's Ulixacaltamide?
Ulixacaltamide is a small molecule commercialized by Praxis Precision Medicines, with a leading Phase III program in Essential Tremor. According...